;PMID: 1360635
;source_file_2947.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..38] = [t:0..38]
;1)sentence:[e:44..192] = [t:44..192]
;2)section:[e:196..230] = [t:196..230]
;3)section:[e:234..346] = [t:234..346]
;4)sentence:[e:350..633] = [t:350..633]
;5)sentence:[e:634..747] = [t:634..747]
;6)sentence:[e:748..907] = [t:748..907]
;7)sentence:[e:908..1062] = [t:908..1062]
;8)sentence:[e:1063..1173] = [t:1063..1173]
;9)sentence:[e:1174..1462] = [t:1174..1462]
;10)section:[e:1466..1510] = [t:1466..1510]

;section 0 Span:0..38
;Neuropeptides.  1992 Oct;23(2):107-13.
(SEC
  (FRAG (NNP:[0..13] Neuropeptides) (.:[13..14] .) (CD:[16..20] 1992)
        (CC:[21..28] Oct;23-LRB-) (CD:[28..29] 2) (-RRB-:[29..30] -RRB-)
        (::[30..31] :) (CD:[31..34] 107) (HYPH:[34..35] -) (CD:[35..37] 13)
        (.:[37..38] .)))

;sentence 1 Span:44..192
;Modulation of cholecystokinin (CCK) gene-expression in a human neuroblastoma 
;cell line: effects of serum on enhanced CCK and c-fos mRNA expression.
;[58..73]:gene-rna:"cholecystokinin"
;[75..78]:gene-rna:"CCK"
;[107..120]:malignancy-type:"neuroblastoma"
;[162..165]:gene-rna:"CCK"
;[170..175]:gene-rna:"c-fos"
(SENT
  (NP-HLN
    (NP
      (NP (NN:[44..54] Modulation))
      (PP (IN:[55..57] of)
        (NP
          (NML
            (NML (NN:[58..73] cholecystokinin))
            (NML (-LRB-:[74..75] -LRB-) (NN:[75..78] CCK) (-RRB-:[78..79] -RRB-)))
          (NN:[80..84] gene) (HYPH:[84..85] -) (NN:[85..95] expression)))
      (PP (IN:[96..98] in)
        (NP (DT:[99..100] a) (JJ:[101..106] human) (NN:[107..120] neuroblastoma)
            (NN:[122..126] cell) (NN:[127..131] line))))
    (::[131..132] :)
    (NP
      (NP (NNS:[133..140] effects))
      (PP (IN:[141..143] of)
        (NP (NN:[144..149] serum)))
      (PP (IN:[150..152] on)
        (NP
          (NP
            (ADJP-1 (VBN:[153..161] enhanced))
            (NN:[162..165] CCK)
            (NML-2 (-NONE-:[165..165] *P*)))
          (CC:[166..169] and)
          (NP
            (ADJP-1 (-NONE-:[169..169] *P*))
            (NN:[170..175] c-fos)
            (NML-2 (NN:[176..180] mRNA) (NN:[181..191] expression))))))
    (.:[191..192] .)))

;section 2 Span:196..230
;Monstein HJ, Pedersen K, Haahr PM.
(SEC
  (FRAG (NNP:[196..204] Monstein) (NNP:[205..207] HJ) (,:[207..208] ,)
        (NNP:[209..217] Pedersen) (NNP:[218..220] K,) (NNP:[221..226] Haahr)
        (NNP:[227..229] PM) (.:[229..230] .)))

;section 3 Span:234..346
;Department of Clinical Biochemistry (KK 3013), State University Hospital 
;(Rigshospitalet), Copenhagen, Denmark.
(SEC
  (FRAG (NNP:[234..244] Department) (IN:[245..247] of) (NNP:[248..256] Clinical)
        (NNP:[257..269] Biochemistry) (-LRB-:[270..271] -LRB-)
        (NNP:[271..273] KK) (CD:[274..278] 3013) (-RRB-:[278..279] -RRB-)
        (,:[279..280] ,) (NNP:[281..286] State) (NNP:[287..297] University)
        (NNP:[298..306] Hospital) (-LRB-:[308..309] -LRB-)
        (NNP:[309..323] Rigshospitalet) (-RRB-:[323..324] -RRB-)
        (,:[324..325] ,) (NN:[326..336] Copenhagen) (,:[336..337] ,)
        (NNP:[338..345] Denmark) (.:[345..346] .)))

;sentence 4 Span:350..633
;The effect of fetal-calf serum (FCS) and Forskolin (FKN) on cholecystokinin 
;(CCK) and proto-oncogene c-fos mRNA expression in the human neuroblastoma
;cell  line SK-N-MC, cultured in serum free medium was studied by Northern
;blot  analysis and nuclear run-off transcription analysis.
;[410..425]:gene-rna:"cholecystokinin"
;[428..431]:gene-rna:"CCK"
;[452..457]:gene-rna:"c-fos"
;[487..500]:malignancy-type:"neuroblastoma"
(SENT
  (S
    (NP-SBJ-1
      (NP (DT:[350..353] The) (NN:[354..360] effect))
      (PP (IN:[361..363] of)
        (NP
          (NP
            (NP
              (NML (JJ:[364..369] fetal) (HYPH:[369..370] -)
                   (NN:[370..374] calf))
              (NN:[375..380] serum))
            (NP (-LRB-:[381..382] -LRB-) (NN:[382..385] FCS)
                (-RRB-:[385..386] -RRB-)))
          (CC:[387..390] and)
          (NP
            (NP (NN:[391..400] Forskolin))
            (NP (-LRB-:[401..402] -LRB-) (NN:[402..405] FKN)
                (-RRB-:[405..406] -RRB-)))))
      (PP (IN:[407..409] on)
        (NP
          (NP
            (NML
              (NML (NN:[410..425] cholecystokinin))
              (NML (-LRB-:[427..428] -LRB-) (NN:[428..431] CCK)
                   (-RRB-:[431..432] -RRB-)))
            (NML-2 (-NONE-:[432..432] *P*)))
          (CC:[433..436] and)
          (NP
            (NML (AFX:[437..442] proto) (HYPH:[442..443] -)
                 (NN:[443..451] oncogene))
            (NN:[452..457] c-fos)
            (NML-2 (NN:[458..462] mRNA) (NN:[463..473] expression)))))
      (PP (IN:[474..476] in)
        (NP
          (NP (DT:[477..480] the) (JJ:[481..486] human)
              (NN:[487..500] neuroblastoma) (NN:[501..505] cell)
              (NN:[507..511] line))
          (NP
            (NP (NN:[512..519] SK-N-MC))
            (,:[519..520] ,)
            (VP (VBN:[521..529] cultured)
              (NP (-NONE-:[529..529] *))
              (PP (IN:[530..532] in)
                (NP
                  (ADJP (NN:[533..538] serum) (JJ:[539..543] free))
                  (NN:[544..550] medium))))))))
    (VP (VBD:[551..554] was)
      (VP (VBN:[555..562] studied)
        (NP-1 (-NONE-:[562..562] *))
        (PP-MNR (IN:[563..565] by)
          (NP
            (NP (JJ:[566..574] Northern) (NN:[575..579] blot)
                (NN:[581..589] analysis))
            (CC:[590..593] and)
            (NP
              (NML (JJ:[594..601] nuclear) (VB:[602..605] run)
                   (HYPH:[605..606] -) (RP:[606..609] off))
              (NN:[610..623] transcription) (NN:[624..632] analysis))))))
    (.:[632..633] .)))

;sentence 5 Span:634..747
;Addition of FCS or FKN  gradually increased the basal CCK mRNA level
;approximately four to six-fold  after 2-4 h.
;[688..691]:gene-rna:"CCK"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[634..642] Addition))
      (PP (IN:[643..645] of)
        (NP (NN:[646..649] FCS) (CC:[650..652] or) (NN:[653..656] FKN))))
    (ADVP (RB:[658..667] gradually))
    (VP (VBD:[668..677] increased)
      (NP (DT:[678..681] the) (JJ:[682..687] basal) (NN:[688..691] CCK)
          (NN:[692..696] mRNA) (NN:[697..702] level))
      (ADVP-EXT
        (QP (RB:[703..716] approximately) (CD:[717..721] four)
            (TO:[722..724] to) (CD:[725..728] six))
        (HYPH:[728..729] -) (RB:[729..733] fold))
      (PP-TMP (IN:[735..740] after)
        (NP
          (QP (CD:[741..742] 2) (HYPH:[742..743] -) (CD:[743..744] 4))
          (NN:[745..746] h))))
    (.:[746..747] .)))

;sentence 6 Span:748..907
;In contrast, a strong and transient increase of the c-fos  mRNA-level was
;observed, approximately forty to fifty-fold after 50-60 min over 
;unstimulated cells.
;[800..805]:gene-rna:"c-fos"
(SENT
  (S
    (PP (IN:[748..750] In)
      (NP (NN:[751..759] contrast)))
    (,:[759..760] ,)
    (NP-SBJ-1
      (NP (DT:[761..762] a)
        (ADJP (JJ:[763..769] strong) (CC:[770..773] and)
              (JJ:[774..783] transient))
        (NN:[784..792] increase))
      (PP (IN:[793..795] of)
        (NP (DT:[796..799] the)
          (NML (NN:[800..805] c-fos) (NN:[807..811] mRNA))
          (HYPH:[811..812] -) (NN:[812..817] level))))
    (VP (VBD:[818..821] was)
      (VP (VBN:[822..830] observed)
        (NP-1 (-NONE-:[830..830] *))
        (,:[830..831] ,)
        (ADVP-EXT
          (QP (RB:[832..845] approximately) (CD:[846..851] forty)
              (TO:[852..854] to) (CD:[855..860] fifty))
          (HYPH:[860..861] -) (RB:[861..865] fold))
        (PP-TMP (IN:[866..871] after)
          (NP
            (QP (CD:[872..874] 50) (HYPH:[874..875] -) (CD:[875..877] 60))
            (NN:[878..881] min)))
        (PP (IN:[882..886] over)
          (NP (JJ:[888..900] unstimulated) (NNS:[901..906] cells)))))
    (.:[906..907] .)))

;sentence 7 Span:908..1062
;Nuclear run-off transcription analysis indicates that c-fos  mRNA is
;constitutively expressed and transcription may be further stimulated by  FCS
;and FKN.
;[962..967]:gene-rna:"c-fos"
(SENT
  (S
    (NP-SBJ
      (NML (JJ:[908..915] Nuclear) (VB:[916..919] run) (HYPH:[919..920] -)
           (RP:[920..923] off))
      (NN:[924..937] transcription) (NN:[938..946] analysis))
    (VP (VBZ:[947..956] indicates)
      (SBAR (IN:[957..961] that)
        (S
          (S
            (NP-SBJ-1 (NN:[962..967] c-fos) (NN:[969..973] mRNA))
            (VP (VBZ:[974..976] is)
              (ADVP (RB:[977..991] constitutively))
              (VP (VBN:[992..1001] expressed)
                (NP-1 (-NONE-:[1001..1001] *)))))
          (CC:[1002..1005] and)
          (S
            (NP-SBJ-2 (NN:[1006..1019] transcription))
            (VP (MD:[1020..1023] may)
              (VP (VB:[1024..1026] be)
                (ADVP (RBR:[1027..1034] further))
                (VP (VBN:[1035..1045] stimulated)
                  (NP-2 (-NONE-:[1045..1045] *))
                  (PP (IN:[1046..1048] by)
                    (NP-LGS (NN:[1050..1053] FCS) (CC:[1054..1057] and)
                            (NN:[1058..1061] FKN))))))))))
    (.:[1061..1062] .)))

;sentence 8 Span:1063..1173
;Moreover, in SK-N-MC nuclei, transcription of the c-fos gene  clearly
;precedes stimulated CCK-mRNA expression.
;[1113..1118]:gene-rna:"c-fos"
;[1153..1156]:gene-rna:"CCK"
(SENT
  (S
    (ADVP (RB:[1063..1071] Moreover))
    (,:[1071..1072] ,)
    (PP-LOC (IN:[1073..1075] in)
      (NP (NN:[1076..1083] SK-N-MC) (NNS:[1084..1090] nuclei)))
    (,:[1090..1091] ,)
    (NP-SBJ
      (NP (NN:[1092..1105] transcription))
      (PP (IN:[1106..1108] of)
        (NP (DT:[1109..1112] the) (NN:[1113..1118] c-fos) (NN:[1119..1123] gene))))
    (ADVP (RB:[1125..1132] clearly))
    (VP (VBZ:[1133..1141] precedes)
      (NP
        (NML (VBN:[1142..1152] stimulated) (NN:[1153..1156] CCK)
             (HYPH:[1156..1157] -) (NN:[1157..1161] mRNA))
        (NN:[1162..1172] expression)))
    (.:[1172..1173] .)))

;sentence 9 Span:1174..1462
;This suggests that FOS, which  is known to form a AP-1 heterodimer
;transcription complex with the proto-oncogen  product, Jun, may bind to the
;tentative AP-1 binding site, found within the  human CCK promoter and thereby
;modulates basal and enhanced CCK-mRNA expression  in SK-N-MC cells.
;[1193..1196]:gene-generic:"FOS"
;[1296..1299]:gene-protein:"Jun"
;[1370..1373]:gene-rna:"CCK"
;[1424..1427]:gene-rna:"CCK"
(SENT
  (S
    (NP-SBJ (DT:[1174..1178] This))
    (VP (VBZ:[1179..1187] suggests)
      (SBAR (IN:[1188..1192] that)
        (S
          (NP-SBJ
            (NP (NN:[1193..1196] FOS))
            (,:[1196..1197] ,)
            (SBAR
              (WHNP-1 (WDT:[1198..1203] which))
              (S
                (NP-SBJ-1 (-NONE-:[1203..1203] *T*))
                (VP (VBZ:[1205..1207] is)
                  (VP (VBN:[1208..1213] known)
                    (S
                      (NP-SBJ-1 (-NONE-:[1213..1213] *))
                      (VP (TO:[1214..1216] to)
                        (VP (VB:[1217..1221] form)
                          (NP (DT:[1222..1223] a) (NN:[1224..1228] AP-1)
                              (NN:[1229..1240] heterodimer)
                              (NN:[1241..1254] transcription)
                              (NN:[1255..1262] complex))
                          (PP (IN:[1263..1267] with)
                            (NP
                              (NP (DT:[1268..1271] the)
                                (NML (AFX:[1272..1277] proto)
                                     (HYPH:[1277..1278] -)
                                     (NN:[1278..1285] oncogen))
                                (NN:[1287..1294] product))
                              (,:[1294..1295] ,)
                              (NP (NN:[1296..1299] Jun))))))))))))
          (,:[1299..1300] ,)
          (VP (MD:[1301..1304] may)
            (VP (VB:[1305..1309] bind)
              (PP-CLR (TO:[1310..1312] to)
                (NP
                  (NP (DT:[1313..1316] the) (JJ:[1317..1326] tentative)
                      (NN:[1327..1331] AP-1) (NN:[1332..1339] binding)
                      (NN:[1340..1344] site))
                  (,:[1344..1345] ,)
                  (VP
                    (VP (VBN:[1346..1351] found)
                      (NP (-NONE-:[1351..1351] *))
                      (PP-LOC (IN:[1352..1358] within)
                        (NP (DT:[1359..1362] the) (JJ:[1364..1369] human)
                            (NN:[1370..1373] CCK) (NN:[1374..1382] promoter))))
                    (CC:[1383..1386] and)
                    (VP
                      (ADVP (RB:[1387..1394] thereby))
                      (VBZ:[1395..1404] modulates)
                      (NP
                        (NP (JJ:[1405..1410] basal)
                          (NML-2 (-NONE-:[1410..1410] *P*)))
                        (CC:[1411..1414] and)
                        (NP (VBN:[1415..1423] enhanced)
                          (NML-2 (NN:[1424..1427] CCK) (HYPH:[1427..1428] -)
                                 (NN:[1428..1432] mRNA)
                                 (NN:[1433..1443] expression))))
                      (PP (IN:[1445..1447] in)
                        (NP (NN:[1448..1455] SK-N-MC) (NNS:[1456..1461] cells))))))))))))
    (.:[1461..1462] .)))

;section 10 Span:1466..1510
;PMID: 1360635 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1466..1470] PMID) (::[1470..1471] :) (CD:[1472..1479] 1360635)
        (NN:[1480..1481] -LSB-) (NNP:[1481..1487] PubMed) (::[1488..1489] -)
        (NN:[1490..1497] indexed) (IN:[1498..1501] for)
        (NNP:[1502..1510] MEDLINE-RSB-)))
